US FDA classifies company's #Palghar unit as ‘Voluntary Action Indicated’, issues Establishment Inspection Report (#EIR): Bliss GVS Pharma
US FDA conducted a pre-approval #inspection at Palghar unit from March 13-17, 2023
US FDA conducted a pre-approval #inspection at Palghar unit from March 13-17, 2023
#GlandPharma | US FDA issue Establishment Inspection Report (#EIR) for Pashamylaram facility at Hyderabad. EIR from US FDA indicates closure of the #inspection
⭕️ US FDA conducted a #GMP inspection at Pashamylaram unit from August 23-26, 2023
⭕️ US FDA conducted a #GMP inspection at Pashamylaram unit from August 23-26, 2023